they release 1.6 million more 2 doses and in Richmond they say “the WHO problem will be solved”

Until a few days ago, attention to Sputnik V focused on the impossibility get the precious second component. Now, the gaze seems to have shifted to another impossibility: that of the immune to travel, since the vaccine not WHO approved and, therefore, it is not recognized in many countries. In November, the United States would join this stock.

In this context, Bugle He had access to the orders for the release of the vaccine in Russia and was able to know that at that time it will be available to the Argentine government. 1.6 million additional second components. These are those produced by the Richmond laboratory, whose batches must be approved each time the Gamaleya Institute is completed, before they can be authorized in Argentina by ANMAT.

This new batch will contribute to fill the gap which exists today between the first and the second applied dose of the Russian vaccine. About 11 million people were inoculated with component 1 and 6 million with component 2. With the new delivery from Richmond, the difference is. would be limited to 3.5 million. Although it is even less, due to the Moderna vaccines which were used in combination with the Russian vaccine.

The total vaccines delivered by Richmond to date will then be 4.7 million. It’s just part of the 8000000 that the laboratory has already produced (with 3 million pending authorization), plus nearly two million that are currently being manufactured at the Tortuguitas plant.

But for some reason, happiness with Sputnik V it cannot be complete. As the vaccinees begin to see their patterns resolved and receive the second dose, it has emerged another obstacle on the road: news that the United States would block entry of those who have been immunized with this drug from November 1.

This is an obstacle that would complicate many Argentines who have to travel to this country to various reasons. Minister Carla Vizzotti raised the issue on Monday: “Sooner or later, this tension, this uncertainty, must be released depending on whether the WHO has the information to approve it or whether countries accept a vaccine that has many examples of efficiency, not that countries define a health strategy based on something that is not health ”.

Last week it was learned, according to sources from the Russian Direct Investment Fund, that the WHO would be making a new factory inspection production which was questioned in January and which was again banned in April. It would be the last chance before November for the international health organization to pave the way and for Sputnik V to gain global validity.

Sources from the Richmond lab were also convinced it would happen soon: “WHO not a question of safety or efficacy vaccine. More and more reports and clinical studies are published that show how good the product is. This is an administrative matter, paperwork, and political auction ”.

Sources from Richmond added: “They told us that soon this process will be solved. Although the priority is to take care of yourself, of course without neglecting everything else, the possibility of traveling. Even though it is a very small part of the population, don’t minimize it. In some ways, it is good news that today we are talking about travel and not about lack of vaccines ”.

PS